Low-moderate dietary zinc intake (7.51–10.87 mg/day) was associated with a 16% reduced odds of HSV-1 seropositivity and 19% reduced odds of HSV-2 seropositivity compared to the lowest intake group in U.S. adults aged 14-49.
Cross-Sectional (n=6,483)
Yes
Does moderate dietary zinc intake reduce HSV-1 and HSV-2 seropositivity in U.S. adults?
Moderate dietary zinc intake is associated with a reduced risk of HSV-1 and HSV-2 seropositivity in U.S. adults, exhibiting a U-shaped dose-response relationship.
Effect estimate: HSV-1 OR 0.84 (95% CI 0.70-0.99) for low-moderate zinc intake (7.51–10.87 mg/day); HSV-2 OR 0.81 (95% CI 0.66-0.99) for low-moderate zinc intake compared to lowest quartile (95% CI See effect sizes)
p-value: p=HSV-1 p=0.028; HSV-2 p=0.039
Although recent research has demonstrated an association between serum zinc deficiency and susceptibility to various viral infections, the relationship between dietary zinc intake and herpes simplex virus (HSV) seropositivity remains unclear. The National Health and Nutrition Examination Survey (NHANES) (2007–2016) provides data on HSV-1 and HSV-2 status and dietary zinc intake. The associations between dietary zinc and HSV-1 and HSV-2 were evaluated via various statistical methods, including multivariate logistic regression, restricted cubic spline analysis, and subgroup analysis. In total, 6,483 individuals were enrolled, with 58.9% (3,817/6,483) testing positive for HSV-1 and 19.3% (1,253/6,483) testing positive for HSV-2. After adjusting for all covariates in the multivariate logistic regression, compared with the lowest zinc intake group (Q1: 15.63 mg/day) had an OR of 0.84 (95% CI: 0.67–1.04, p = 0.114); for HSV-2, Q2 had an OR of 0.80 (95% CI: 0.64–1.00, p = 0.050), Q3 had an OR of 0.81 (95% CI: 0.64–1.02, p = 0.069), and Q4 had an OR of 0.75 (95. Dietary zinc intake exhibited a U-shaped association with HSV-1 and HSV-2 seropositivity, indicating that moderate zinc intake has a protective effect. Not applicable.
Liu et al. (Thu,) conducted a cross-sectional in U.S. adults aged 14-49 years with available dietary zinc intake and HSV-1/HSV-2 serostatus data (n=6,483). Dietary zinc intake vs. Lowest zinc intake quartile (<7.51 mg/day) was evaluated on HSV-1 and HSV-2 seropositivity (HSV-1 OR 0.84 (95% CI 0.70-0.99) for low-moderate zinc intake (7.51–10.87 mg/day); HSV-2 OR 0.81 (95% CI 0.66-0.99) for low-moderate zinc intake compared to lowest quartile, 95% CI See effect sizes, p=HSV-1 p=0.028; HSV-2 p=0.039). Low-moderate dietary zinc intake (7.51–10.87 mg/day) was associated with a 16% reduced odds of HSV-1 seropositivity and 19% reduced odds of HSV-2 seropositivity compared to the lowest intake group in U.S. adults aged 14-49.